Arvinas (ARVN) Q3 2026 earnings review
Arvinas cuts its cash burn, but pipeline delays persist
Arvinas, a biotechnology company developing drugs that destroy disease-causing proteins, cut its spending sharply while its clinical timeline stayed uneven. Research and overhead costs excluding one-offs fell 25% to $54 million after partner Rigel Pharmaceuticals took over the Veppanu breast cancer pill, and collecting a $50 million milestone kept cash at $559 million, above what the prior burn rate pointed to by our math. Chief executive Randy Teel kept the cash outlook into the second half of 2028 and reported improved eye movement in Parkinson's patients taking brain drug ARV-102.
| Research and overhead, excluding one-offs | $53.5M -25% from a year ago |
|---|---|
| Cash and marketable securities | $558.9M down $9M from last quarter |
| Veppanu royalty revenue | $0.5M first commercial sales by partner Rigel |
| Cash runway outlook | Unchanged funds the plan into the second half of 2028 |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because tighter cost control offsets another quiet retreat in the drug pipeline. Lower quarterly spending removes pressure on the 2028 cash plan, and the Parkinson's biomarker gains support the science behind protein degradation. The bad news: Arvinas quietly dropped the promised 2026 clinical readout for its KRAS cancer drug ARV-806 and confirmed its US brain trial remains on regulatory hold until it finishes a European study first.
The question now is whether early human data from the remaining cancer and nerve drugs can justify the business beyond its cash pile. One view is that December's lymphoma readout will prove the platform works in blood cancers; the other is that early low-dose cohorts and repeated timeline delays will leave the pipeline unproven until mid-2027. The December hematology conference presentation for lymphoma drug ARV-393 is the first test.
🐂 Bull Case
Deep Cost Cuts Give the Cash Plan Breathing Room
Arvinas develops drugs that destroy disease-causing proteins, and its main financial promise is making its $558.9 million cash pile last "into the second half of 2028". Handing its breast cancer drug vepdegestrant to partner Rigel Pharmaceuticals and cutting staff lowered quarterly research and overhead costs much faster than in prior quarters.
- Research and overhead excluding one-offs: $53.5 million, down 25% from a year ago by our math
- Vepdegestrant external research spend: down $14.2 million from a year ago
- Newer Phase 1 drug spend (ARV-027, ARV-6723, ARV-393): up $11.1 million combined
- Quarterly cash burn after interest income: $48.1 million by our math
This drop matters because keeping cash into late 2028 allows at most $69.9 million of quarterly burn over the next eight quarters by our math. Running at $48.1 million leaves room to pay down the $46.4 million owed on old drug partnerships and still fund growing Phase 1 trials without selling new shares.
What to watch: fourth-quarter research expenses excluding stock pay and restructuring. A figure below $50 million would confirm the lower cost base holds even as three Phase 1 trials add patients.
Parkinson's Drug Improved Patient Eye Movement in Phase 1
Arvinas argues that destroying the whole LRRK2 protein, which is linked to brain-cell damage, works better than merely blocking its enzyme activity as rival pills do. At an October medical meeting, the biotech group shared new Phase 1 results for ARV-102, its oral LRRK2 degrader, in patients with Parkinson's disease.
Daily doses of 20 milligrams or more cut LRRK2 protein in spinal fluid by at least 50% and reduced markers of brain inflammation, the company said. Those protein drops lined up with gains in "an objective measure of impaired eye movement associated with Parkinson’s disease" after 28 days of treatment. Showing a physical change in eye control alongside cleaner spinal-fluid markers gives Arvinas clinical evidence that destroying the whole protein reaches deep brain pathways.
What to watch: European and British regulatory clearance for the Phase 1b trial in progressive supranuclear palsy, a fatal brain disorder affecting eye movement and balance, planned for 2027. Approval to dose patients over several months will test whether these 28-day eye-movement gains turn into slower disease progression.
Partnered Breast Cancer Drug Earns Its First Royalties
Earlier this year Arvinas and partner Pfizer licensed global rights for Veppanu (vepdegestrant), their approved breast cancer pill, to Rigel Pharmaceuticals so Arvinas could avoid paying for a sales force. Rigel put the drug on the US market in August, generating $0.5 million in initial royalty revenue for Arvinas this quarter.
The drug maker also started dosing solid-tumor patients in the Phase 1/2 trial of ARV-6723, an oral pill that destroys HPK1, a protein that brakes the immune system. Collecting early royalties while launching a new clinical trial shows the partner-first approach is shifting money from commercial overhead into early drug discovery.
What to watch: fourth-quarter royalty revenue from Rigel, which will reflect the first full quarter of US breast cancer sales. A rising figure will show how much commercial cash will offset internal research bills.
🐻 Bear Case
KRAS Cancer Drug Drops Off the Milestone Schedule
"We are prioritizing investments where emerging evidence supports our goal of creating transformative medicines for patients," chief executive Randy Teel said. One quarter ago, Arvinas promised to share initial Phase 1 clinical data in the second half of 2026 for ARV-806, its drug targeting KRAS G12D mutations in solid tumors.
This quarter the biotech group removed the ARV-806 data readout from its milestone schedule and left the program out of its corporate presentation pipeline chart. Teel's opening quote instead highlighted upcoming data from only three programs: "our BCL6, polyQ-AR, and HPK1 degraders". The release mentions ARV-806 only in the company boilerplate, repeating that it "plans to seek an out-licensing agreement for any additional clinical trials of ARV-806".
Dropping a promised year-end readout cuts against the claim of steady clinical execution, because ARV-806 was the single largest recipient of new external research spending during the first half of 2026. If Arvinas does not publish the Phase 1 results at a medical meeting, investors cannot judge whether the data is strong enough to attract a partner.
What to watch: whether Arvinas publishes ARV-806 Phase 1 numbers or signs a licensing deal before the fourth-quarter report. Continued silence would indicate that the money spent on the trial failed to produce partner-ready results.
US Hold Forces Brain Trial to Europe First
Arvinas wants to test ARV-102 in patients with progressive supranuclear palsy (PSP), a rare and fatal brain disorder with no approved treatments. Earlier this year US regulators placed a clinical hold on the program because of safety findings in high-dose monkey studies, delaying the trial from 2026 into 2027.
The company now plans to file applications to run the Phase 1b PSP trial in the European Union in the fourth quarter of 2026 and in the United Kingdom in early 2027. Its US application "remains on hold in the U.S.", and Arvinas stated its new goal is "to include U.S. sites in future trials after completing the Phase 1b clinical trial".
This change matters because the Food and Drug Administration will not allow US patient dosing until Arvinas finishes the European study first. Running Phase 1b overseas before re-entering the US stretches the timeline and adds regulatory risk to the company's lead brain program.
What to watch: clearance of the European clinical trial application, which Arvinas plans to submit in the fourth quarter of 2026. Any delay or dosing restriction from European regulators would push the entire neuro-degeneration program further behind.
December Lymphoma Readout Covers Only Early Doses
"The upcoming data from our BCL6, polyQ-AR, and HPK1 degraders will begin to define the opportunity for these programs to change the treatment landscape," Teel said. ARV-393 is an oral pill designed to destroy BCL6, a protein that drives non-Hodgkin lymphoma, and Arvinas submitted its first Phase 1 data for the December hematology meeting.
The December presentation will show safety and drug levels from early dose-escalation groups, "with preliminary efficacy from T-cell lymphomas", a smaller subtype of the blood cancer. Tumor-shrinkage data for the much larger B-cell lymphoma group and results combining ARV-393 with antibody drug glofitamab will not arrive until mid-2027. Because most early patients received low starting doses, a small number of tumor responses in December could leave the drug's commercial potential unproven for another six months.
What to watch: the exact count of tumor shrinkages and the BCL6 protein destruction percentage at the December 12–15 hematology meeting. Low response rates in T-cell lymphoma would put more pressure on the mid-2027 B-cell readout.
Risks this quarter didn't answer
Three standing concerns from last quarter received no new answers in the third-quarter release or presentation.
- Chief Medical Officer vacancy: former clinical head Noah Berkowitz left in July, and the release names no permanent replacement ahead of the December and 2027 data readouts.
- Veppanu commercial terms: Arvinas booked $0.5 million in royalties, but neither Rigel's underlying sales figure nor the revenue share on future non-US deals was disclosed.
- Rival drug classes: competitors are advancing rival BCL6 degraders and KRAS blockers, and clinical comparisons must wait for Arvinas's 2027 mid-stage readouts.
💲 Other KPIs
Cash and marketable securities fell by $9.0 million from the second quarter, down from a $47.0 million drop in the prior period. Collecting a $50 million regulatory approval milestone from Pfizer cushioned the balance; without that receivable collection, cash fell by $57.5 million by our math.
The collaboration liability — money Arvinas owes for remaining vepdegestrant clinical trial wind-down costs after licensing the drug out — declined by $6.3 million from $52.7 million in the second quarter by our math. Of the remaining balance, $28.2 million is due within twelve months and $18.2 million is long-term.
Weighted average diluted shares fell 10.7% from 73.2 million a year ago because the biotech company bought back 10.0 million shares during the second half of 2025. Compared with the first and second quarters of 2026, the share count scarcely moved as management kept the buyback program paused.
🔮 Guidance
Unchanged. Arvinas expects its $558.9 million in cash and securities to fund planned operations and equipment purchases "into the second half of 2028". By our math, reaching the third quarter of 2028 allows up to $69.9 million of cash burn per quarter, and if the third quarter's $48.1 million net operating burn holds, cash would last more than 10 quarters even after paying the $46.4 million collaboration liability.
❓ Key Questions
Why did ARV-806 Phase 1 data leave the schedule?
Until last quarter Arvinas promised initial Phase 1 data for its KRAS G12D cancer drug in the second half of 2026. The company removed that milestone without saying whether it will publish the results or only show them privately to potential partners.
What did the FDA require to lift the ARV-102 hold?
Arvinas now expects to include US sites only after completing its Phase 1b PSP trial in Europe and the UK. Investors need to know whether US regulators asked for full European human safety data before lifting the clinical hold.
Will quarterly operating expenses stay near $54 million?
Research and overhead costs excluding one-offs dropped from $69.8 million in Q2 to $53.5 million in Q3 as vepdegestrant spending rolled off. Management did not say how quickly costs will climb back up as three Phase 1 trials expand.
Where does the Chief Medical Officer search stand?
Former Chief Medical Officer Noah Berkowitz departed in July, and the third-quarter release named no successor. With three Phase 1 readouts scheduled between December 2026 and late 2027, clinical leadership is a live operational question.